<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23425">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01972113</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000912</org_study_id>
    <nct_id>NCT01972113</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin K Supplementation on Markers of Diabetes Risk in Obese Children</brief_title>
  <official_title>Efficacy and Optimal Dose Finding Study of Vitamin K on Glucose Metabolism in Children at Risk for Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgia Regents University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NattoPharma, ASA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgia Regents University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given that glutamate carboxylation or decarboxylation is key to the metabolic role of
      osteocalcin (at least in mouse models) and that carboxylation is vitamin K dependent, it is
      critical to isolate the effect of vitamin K manipulation on carboxylation of osteocalcin and
      its subsequent effect on glucose metabolism in clinical trials. The purpose of this
      randomized, double-blind, placebo-controlled clinical trial in obese children is to
      determine whether eight weeks of daily supplementation with vitamin K2 (menaquinone-7) can
      improve markers in blood associated with diabetes risk.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The first primary aim is to determine if the vitamin K-induced change in carboxylation of osteocalcin effects insulin sensitivity in a dose-dependent manner. Insulin sensitivity will be calculated from plasma insulin and glucose concentrations measured during a two-hour oral glucose tolerance test by using the oral glucose minimal model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-cell function</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The second primary aim is to determine if the vitamin K-induced change in carboxylation of osteocalcin effects beta-cell function in a dose-dependent manner. Beta-cell function, as assessed by dynamic beta-cell responsitivity, will be calculated from plasma glucose and C-peptide concentrations measured during a two-hour oral glucose tolerance test by using the oral C-peptide minimal model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in coagulation</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Coagulation-related parameters (i.e., activated thrombin and endogenous thrombin potential) will be assessed at baseline and 8 weeks to determine that vitamin K2 has no procoagulant effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum adipokine concentrations</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adipokines leptin and adiponectin will be measured in fasting serum at baseline and 8 weeks to explore whether changes in serum adipokine concentrations are influenced by vitamin K2 supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of sex, race, bone age, and pubertal stage on changes in glucose metabolism (insulin sensitivity and beta-cell function)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Moderation effects of sex, race, bone age, and pubertal stage in the associations of vitamin K-induced changes in carboxylation of osteocalcin on markers of glucose metabolism will be determined.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Beta-Cell Dysfunction</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Placebo-Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo-control group will take two placebo softgel capsules every day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose Vitamin K2 (45 mcg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Vitamin K2 (90 mcg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo-Control</intervention_name>
    <description>two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)</description>
    <arm_group_label>Placebo-Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)</intervention_name>
    <description>one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks</description>
    <arm_group_label>Low-Dose Vitamin K2 (45 mcg/d)</arm_group_label>
    <other_name>menaquinone-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)</intervention_name>
    <description>two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks</description>
    <arm_group_label>High-Dose Vitamin K2 (90 mcg/d)</arm_group_label>
    <other_name>menaquinone-7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 8 to 11 years

          -  Obese but otherwise healthy (obese is defined as having body mass index greater than
             or equal to 95th percentile for children of same age and sex)

          -  Sedentary (no regular physical activity or sports program greater than one hour per
             week)

          -  Subject and parent/guardian understands the study protocol and agrees to comply with
             it

          -  Informed Consent Form signed by the parent/guardian and assent signed by the subject

        Exclusion Criteria:

          -  Subjects using vitamin supplements containing vitamin k

          -  Subjects with (a history of) metabolic or gastrointestinal diseases including hepatic
             disorders

          -  Subjects presenting chronic degenerative and/or inflammatory diseases

          -  Subjects receiving systemic treatment or topical treatment likely to interfere with
             evaluation of the study parameters (salicylates, antibiotics)

          -  Subjects receiving corticosteroid treatment

          -  Subjects using oral anticoagulants

          -  Subjects with a history of soy allergy

          -  Subjects who have participated in a clinical study more recently than one month
             before the current study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman K Pollock, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Medical College of Georgia, Georgia Regents University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norman K Pollock, Ph.D.</last_name>
    <phone>706-721-5424</phone>
    <email>npollock@gru.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical College of Georgia; Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norman K Pollock, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pollock NK, Bernard PJ, Gower BA, Gundberg CM, Wenger K, Misra S, Bassali RW, Davis CL. Lower uncarboxylated osteocalcin concentrations in children with prediabetes is associated with beta-cell function. J Clin Endocrinol Metab. 2011 Jul;96(7):E1092-9. doi: 10.1210/jc.2010-2731. Epub 2011 Apr 20.</citation>
    <PMID>21508147</PMID>
  </reference>
  <reference>
    <citation>Gower BA, Pollock NK, Casazza K, Clemens TL, Goree LL, Granger WM. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and β-cell function in overweight adults. J Clin Endocrinol Metab. 2013 Jul;98(7):E1173-80. doi: 10.1210/jc.2013-1203. Epub 2013 Apr 24.</citation>
    <PMID>23616149</PMID>
  </reference>
  <reference>
    <citation>Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013 Jan;9(1):43-55. doi: 10.1038/nrendo.2012.201. Epub 2012 Nov 13. Review.</citation>
    <PMID>23147574</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>October 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgia Regents University</investigator_affiliation>
    <investigator_full_name>Norman Pollock</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Vitamin K</keyword>
  <keyword>Vitamin K2</keyword>
  <keyword>Menaquinone-7</keyword>
  <keyword>Osteocalcin</keyword>
  <keyword>Children</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Beta-cell function</keyword>
  <keyword>Prediabetes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
